Trial Profile
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Apr 2019 Results published in the Clinical Cancer Research
- 23 Apr 2018 Status changed from active, no longer recruiting to completed.
- 31 Jan 2018 Planned End Date changed from 31 Mar 2020 to 28 Mar 2019.